Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07077395
PHASE2

Finding Links Between Hot flASHes and CardioVascular Disease

Sponsor: Massachusetts General Hospital

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improve blood vessel health?

Key Details

Gender

FEMALE

Age Range

40 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2026-04

Completion Date

2030-10

Last Updated

2026-02-12

Healthy Volunteers

No

Interventions

DRUG

elinzanetant - reference formulation

elinzanetant 120 mg daily x 12 weeks

DRUG

placebo

placebo daily x 12 weeks

Locations (2)

Massachusetts General Hospital

Boston, Massachusetts, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States